The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Participants will receive single of JMKX003142 6mg
Participants will receive single of JMKX003142 30mg
Participants will receive single of Placebo
The effect of JMKX003142 treatment on placebo-corrected change from baseline QT interval (ΔΔQTc)
Time frame: Up to 24 hours post dose
Placebo-corrected Change From Baseline in Heart Rate After JMKX003142 treatment
Time frame: Up to 72 hours post dose
Placebo-corrected Change From Baseline in QRS after JMKX003142 treatment
Time frame: Up to72 hours post dose
Placebo-corrected Change From Baseline in PR Interval After JMKX003142 treatment
Time frame: Up to 72 hours post dose
Number of Participants With Treatment-emergent Changes in T-wave Morphology and U-wave Presence
Time frame: Up to 72 hours post dose
Incidence of adverse events to assess the safety of single-dose administration of JMKX003142
Time frame: Up to 72 hours post dose
Maximum Observed Plasma Concentration (Cmax) of JMKX003142
Time frame: Up to 72 hours post dose
Time to Maximum Observed Plasma Concentration (Tmax) of JMKX003142
Time frame: Up to 72 hours post dose
Apparent Terminal Elimination Half-life (T1/2) of JMKX003142
Time frame: Up to 72 hours post dose
Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) for JMKX003142
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 72 hours post dose
AUC From Time 0 to Infinity (AUCinf) for JMKX003142
Time frame: Up to 72 hours post dose